Business
Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (ȁ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access\n\n\n\n VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC).\n \n\n DTC eligibility streamlines the process for U.S. investors to trade Rakovina shares, enhancing liquidity and broadening market accessibility. DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC), the largest securities depository in the world, providing settlement services to major U.S. stock exchanges.\n \n\n “Achieving DTC eligibility is a meaningful step forward in increasing Rakovina’s visibility and accessibility to a broader base of institutional and retail investors,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “It removes a key barrier to efficient trading in the U.S., enhances liquidity, and establishes the foundation for deeper engagement with U.S. capital markets as we continue to execute our growth strategy.”\n \n\n\n Supporting Strategic Growth and Shareholder Value\n \n\n\n The designation eliminates previous barriers to entry for U.S. investors by enabling Rakovina shares to be traded electronically, reducing costs and processing times. This development supports the company’s broader strategy to increase market participation and deliver long-term value to shareholders.\n \n\n The DTC announcement comes as Rakovina continues to advance its preclinical programs and explore strategic partnerships in AI-enhanced diagnostics and oncology therapeutics. Additional corporate developments are expected in the coming months as the company builds on its momentum and executes on its strategic roadmap.\n \n\n\n About Rakovina Therapeutics Inc.\n \n\n\n Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep...